This study aims to analyse the quantity and content of publicly discoverable statements that US-based medical societies issued regarding the 2023 escalation of violence in Palestine and Israel.

We conducted a mixed-methods study using an explanatory sequential design.

Inclusion criteria were defined as US-based medical societies from the American Medical Association House of Delegates, Council of Medical Specialty Societies (CMSS), or Association of American Medical Colleges (AAMC) Council for Academic Specialty Societies, yielding 186 US-based professional medical societies. Descriptive statistics and oods ratios (ORs) were used to assess the association between society characteristics and odds of statement issuance. A qualitative inductive and deductive thematic approach was employed to identify themes from public statements made from 7 October 2023 to 7 December 2023.

22 professional medical societies (N=22/186, 11.83%) issued 20 unique public statements regarding violence in Israel and Palestine. Exploratory OR analyses suggested associations between statement issuance and several society characteristics, though CIs were wide and thus underscored uncertainty regarding the magnitude of these associations. Exploratory OR analyses suggested that statement issuance was associated with possession of a lobbying arm (OR 26.83, 95% CI 3.53 to 204.25, p

Most professional medical societies did not make a public statement regarding violence in Palestine and Israel, and societies that previously engaged in political or international advocacy were more likely to issue a statement. Statements generally avoided any historical, contextual, or geopolitical framing and were more likely to reference Israeli victims than Palestinian victims of violence as well as violence by Hamas than Israeli state violence.

The Comprehensive High-dose Aphasia Treatment (CHAT) programme is an intensive comprehensive aphasia programme, which aims to address evidence-practice gaps in aphasia rehabilitation where there are known barriers to service delivery requiring implementation strategies. The aims of this study are to (1) evaluate the clinical implementation of the CHAT programme, (2) assess the clinical effectiveness of CHAT compared with usual care in rehabilitation services and (3) determine whether the real-world implementation of CHAT compared with usual care is cost-effective.

Four participant groups will be recruited across six hospital and health services Australia-wide to participate in a type 3 hybrid effectiveness-implementation study: (1) people with aphasia, (2) support persons, (3) treating clinicians and students and (4) clinical stakeholders (eg, managers). This before-and-after study will include three time periods: (1) ‘usual care’ where people with aphasia will receive their usual care aphasia therapy, (2) ‘implementation transition’ where clinicians will be trained to deliver CHAT and (3) ‘intervention implementation’ where people with aphasia will receive the CHAT programme (ie, 50 hours of evidence-based aphasia therapy over 8 weeks). Evidence-based implementation strategies will be used to facilitate implementation within participating rehabilitation services. The primary outcome is delivery of evidence-based aphasia treatment (ie, CHAT) as measured by a composite score of quality indicators. Clinical effectiveness outcomes, measuring change in language impairment, communication effectiveness, confidence and quality of life, and implementation outcomes will also be examined. We will also conduct an embedded mixed-methods process evaluation and economic evaluation.

This study has been approved by the Royal Brisbane and Women’s Hospital Human Research Ethics Committee (HREC/2021/QRBW/72154). Outputs will include conference presentations, publications and a training package to optimise implementation of aphasia treatment in rehabilitation service contexts.

Australian New Zealand Clinical Trials Registry (ANZCTR) prospective registration ACTRN12621001765819. Trial registered 23 December 2021. https://anzctr.org.au/Trial/Registration/TrialReview.aspx?id=381365&isReview=true.